Aarvik Therapeutics combines its unique, proprietary modular MUTTA (MUlti-epitope Targeting Tetravalent Antibody) platform with multiple target mechanisms to develop novel molecules with an improved therapeutic index for oncology targets. Backed by the extensive scientific, research, development and business expertise of its founders, Board, SAB and team members, Aarvik Therapeutics is applying its vision and passion to create transformational benefit for cancer patients.
